プロトオンコジーンチロシンプロテインキナーゼROS治療薬市場:パイプラインレビュー(2020年上半期)

◆英語タイトル:Proto Oncogene Tyrosine Protein Kinase ROS - Pipeline Review, H1 2020
◆商品コード:GDATA20MY0887
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2020年2月28日
◆ページ数:90
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,500 ⇒換算¥367,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD7,000 ⇒換算¥735,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD10,500 ⇒換算¥1,102,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Proto Oncogene Tyrosine Protein Kinase ROS – Pipeline Review, H1 2020
Summary

According to the recently published report ‘Proto Oncogene Tyrosine Protein Kinase ROS – Pipeline Review, H1 2020′; Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) pipeline Target constitutes close to 9 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes.

Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) – Proto-oncogene tyrosine-protein kinase ROS is an enzyme that in humans is encoded by the ROS1 gene. It activates several downstream signaling pathways related to cell differentiation, proliferation, growth and survival including the PI3 kinase-mTOR signaling pathway. It mediates the phosphorylation of PTPN11, an activator of this pathway. It phosphorylate and activate the transcription factor STAT3 to control anchorage-independent cell growth. It mediates the phosphorylation and the activation of VAV3, a guanine nucleotide exchange factor regulating cell morphology.

The report ‘Proto Oncogene Tyrosine Protein Kinase ROS – Pipeline Review, H1 2020′ outlays comprehensive information on the Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II and Phase I stages are 1, 2, 3 and 2 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively.

Report covers products from therapy areas Oncology and Genetic Disorders which include indications Non-Small Cell Lung Cancer, Anaplastic Large Cell Lymphoma (ALCL), Neuroblastoma, Solid Tumor, Bile Duct Cancer (Cholangiocarcinoma), Glioblastoma Multiforme (GBM), Metastatic Colorectal Cancer, Non-Hodgkin Lymphoma, Breast Cancer, Central Nervous System (CNS) Tumor, Colorectal Cancer, Gallbladder Cancer, Head And Neck Cancer, Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis), Melanoma, Ovarian Cancer, Renal Cell Carcinoma, Salivary Gland Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Adenocarcinoma, Adenocarcinoma Of The Gastroesophageal Junction, Anaplastic Thyroid Cancer, Angiosarcoma, Astrocytoma, Brain Cancer, Clear Cell Squamous Cell Carcinoma, Esophageal Cancer, Fibrosarcoma, Gastric Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hormone Sensitive Breast Cancer, Letterer-Siwe Disease (Multifocal and multisystemic (disseminated) Langerhans-cell histiocytosis), Liver Cancer, Lymphoma, Malignant Neoplasms, Malignant Pleural Mesothelioma, Mantle Cell Lymphoma, Metastatic Biliary Tract Cancer, Metastatic Breast Cancer, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Melanoma, Metastatic Ovarian Cancer, Metastatic Pancreatic Cancer, Metastatic Transitional (Urothelial) Tract Cancer, Metastatic Uveal Melanoma, Neuroendocrine Tumors, Non-Small Cell Lung Carcinoma, Osteolytic Bone Metastasis, Papillary Renal Cell Carcinoma, Papillary Thyroid Cancer, Pediatric Diffuse Intrinsic Pontine Glioma, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Rhabdomyosarcoma, Sarcomas, Soft Tissue Sarcoma, Synovial Sarcoma, Triple-Negative Breast Cancer (TNBC), Uterine Cancer and Uveal Melanoma.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1)
- The report reviews Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) – Overview
Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) – Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) – Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) – Companies Involved in Therapeutics Development
AnHeart Therapeutics Inc
Ascentage Pharma Group International
Eli Lilly and Co
F. Hoffmann-La Roche Ltd
Pfizer Inc
Turning Point Therapeutics Inc
Xcovery Holding Company LLC
Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) – Drug Profiles
APG-2449 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
crizotinib – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DS-6051 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ensartinib – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
entrectinib – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lorlatinib – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
merestinib – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
repotrectinib – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
WY-135 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) – Dormant Products
Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) – Product Development Milestones
Featured News & Press Releases
Feb 21, 2020: Chugai obtains approval for additional indication of Rozlytrek for ROS1 fusion-positive Non-Small Cell Lung Cancer
Jan 15, 2020: Crizotinib in NSCLC with a MET exon 14 alteration
Dec 26, 2019: Chugai obtains approval for expanded use of FoundationOne CDx Cancer Genomic Profile as a companion diagnostic of Rozlytrek for ROS1-positive Lung Cancer
Dec 13, 2019: Lancet Oncology: Entrectinib effective, well-tolerated against ROS1 and NTRK lung cancers, especially with brain metastases
Nov 12, 2019: Turning Point Therapeutics initiates phase 1/2 clinical study of Repotrectinib in pediatric patients
Nov 08, 2019: Crizotinib in c-MET- or ROS1-positive Non-Small Cell Lung Cancer
Oct 30, 2019: European Society for Medical Oncology: Phase I/II study results with Lorlatinib in ROS1-positive advanced NSCLC
Oct 29, 2019: Vanderbilt Oncologists publish results of first study to demonstrate clinical utility of resolution liquid biopsy assay to monitor response and resistance to Ensartinib
Oct 17, 2019: The Lancet Respiratory Medicine published study shows Ensartinib holds promise as a new treatment option for ALK-positive Non-Small Cell Lung Cancer (NSCLC)
Sep 25, 2019: Preclincal results of Baoyuan’s next-generation ROS1/NTRK inhibitor AB-106 published in Nature Communications
Sep 06, 2019: Chugai files for expanded use of FoundationOne CDx Cancer Genomic Profile as a companion diagnostic of Rozlytrek for ROS1-positive NSCLC
Sep 04, 2019: Chugai launches Rozlytrek, an Anticancer Agent for the treatment of NTRK Fusion-Positive Solid Tumors
Sep 03, 2019: Turning Point Therapeutics announces updated interim clinical data of Repotrectinib
Aug 21, 2019: ROZLYTREK (entrectinib), FDA approved for hard-to-treat NTRK fusion-positive tumors, available at Biologics by McKesson
Aug 16, 2019: FDA approves Roche Rozlytrek (entrectinib) for people with ROS1-positive, metastatic non-small cell lung cancer and NTRK gene fusion-positive solid tumours
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indications, H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..2), H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..3), H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Products under Development by Companies, H1 2020 (Contd..3), H1 2020
Products under Development by Companies, H1 2020 (Contd..4), H1 2020
Products under Development by Companies, H1 2020 (Contd..5), H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by AnHeart Therapeutics Inc, H1 2020
Pipeline by Ascentage Pharma Group International, H1 2020
Pipeline by Eli Lilly and Co, H1 2020
Pipeline by F. Hoffmann-La Roche Ltd, H1 2020
Pipeline by Pfizer Inc, H1 2020
Pipeline by Turning Point Therapeutics Inc, H1 2020
Pipeline by Xcovery Holding Company LLC, H1 2020
Dormant Projects, H1 2020

【掲載企業】

AnHeart Therapeutics Inc
Ascentage Pharma Group International
Eli Lilly and Co
F. Hoffmann-La Roche Ltd
Pfizer Inc
Turning Point Therapeutics Inc
Xcovery Holding Company LLC

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[プロトオンコジーンチロシンプロテインキナーゼROS治療薬市場:パイプラインレビュー(2020年上半期)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆